Document is current
Any future updates will be listed below
-
Authors
Yang, Xinbo https://orcid.org/0000-0002-1755-1349
Garner, Lee I.
Zvyagin, Ivan V. https://orcid.org/0000-0002-1769-9116
Paley, Michael A. https://orcid.org/0000-0001-8724-3176
Komech, Ekaterina A. https://orcid.org/0000-0002-3629-902X
Jude, Kevin M. https://orcid.org/0000-0002-3675-5136
Zhao, Xiang
Fernandes, Ricardo A.
Hassman, Lynn M.
Paley, Grace L.
Savvides, Christina S.
Brackenridge, Simon https://orcid.org/0000-0002-0587-7560
Quastel, Max N. https://orcid.org/0000-0001-6551-4713
Chudakov, Dmitriy M.
Bowness, Paul
Yokoyama, Wayne M. https://orcid.org/0000-0002-0566-7264
McMichael, Andrew J. https://orcid.org/0000-0002-9101-7478
Gillespie, Geraldine M. https://orcid.org/0000-0002-1075-870X
Garcia, K. Christopher https://orcid.org/0000-0001-9273-0278
- License Information
-
More Information
Article History
Received: 5 June 2021
Accepted: 1 November 2022
First Online: 7 December 2022
Competing interests
: M.A.P. has received research support from Eli Lilly and Company paid to the university and served as a consultant for AbbVie, Priovant Therapeutics and JK MarketResearch. The remaining authors declare no competing interests.
